Yu Ren

Department Of Head And Neck Oncology
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Journal: Hematology (Amsterdam, Netherlands)
Published: June 04, 2026

Design, synthesis, and biological evaluation of pyrrolo[2,3-c]pyridin-7-one derivatives as PKMYT1 inhibitors targeting CCNE1-amplified cancers.

Design, synthesis, and biological evaluation of pyrrolo[2,3-c]pyridin-7-one derivatives as PKMYT1 inhibitors targeting CCNE1-amplified cancers.

Journal: European journal of medicinal chemistry
Published: May 27, 2026

Single-cell analysis reveals IL1B+ macrophages promote lung metastasis in adenoid cystic carcinoma.

Single-cell analysis reveals IL1B+ macrophages promote lung metastasis in adenoid cystic carcinoma.

Journal: Cancer letters
Published: April 13, 2026

Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia.

Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia.

Journal: Cancer cell
Published: July 18, 2025

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.

Journal: British journal of haematology
Published: July 03, 2025

CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.

CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.

Journal: Nature communications
Published: May 29, 2025

Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy.

Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy.

Journal: Cancer research communications
Published: May 19, 2025

A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.

A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 30, 2025

Osteopontin promotes tumor microenvironment remodeling and therapy resistance.

Osteopontin promotes tumor microenvironment remodeling and therapy resistance.

Journal: Cancer letters
Published: February 06, 2025

Reprogramming tumor-associated macrophages and blocking PD-L1 via engineered outer membrane vesicles to enhance T cell infiltration and cytotoxic functions.

Reprogramming tumor-associated macrophages and blocking PD-L1 via engineered outer membrane vesicles to enhance T cell infiltration and cytotoxic functions.

Journal: Journal of nanobiotechnology
Published: January 04, 2025

SIRT6 Ameliorates Cancer Cachexia-Associated Adipose Wasting by Suppressing TNFR2 Signalling in Mice.

SIRT6 Ameliorates Cancer Cachexia-Associated Adipose Wasting by Suppressing TNFR2 Signalling in Mice.

Journal: Journal of cachexia, sarcopenia and muscle
Published: August 27, 2024

Polo-like kinase 4 accelerates glioma malignant progression and vasculogenic mimicry by phosphorylating EphA2.

Polo-like kinase 4 accelerates glioma malignant progression and vasculogenic mimicry by phosphorylating EphA2.

Journal: Cancer letters
Published: August 21, 2024
Showing 1-12 of 72

Last Updated: 09/26/2026